An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients With Prostate Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Mar 2024 Results evaluating the A2AR antagonist AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer, published in the Cancer Immunology Immunotherapy
29 May 2023 Status changed from active, no longer recruiting to completed.
18 Feb 2023 Interim results from Arm B (Arm A to be reported elsewhere) assessing safety and efficacy (n=30; As of August 10, 2021) of AZD4635 in combination with durvalumab (Arm A) or with durvalumab + cabazitaxel (Arm B) in patients with metastatic castrate-resistant prostate cancer, presented at the 2023 Genitourinary Cancers Symposium.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com